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Abstract 
microRNAs (miRNAs) play an important role in cancer prognosis. They are 
small molecules, approximately 17-25 nucleotides in length, and their high stability in 
human serum supports their use as novel diagnostic biomarkers of cancer and other 
pathological conditions. In this study, we analyzed the expression patterns of miR-21 
and miR-221 in the serum from a total of 100 Egyptian female subjects with breast 
cancer, fibroadenoma, and healthy control subjects. Using microarray-based 
expression profiling followed by real-time polymerase chain reaction validation, we 
compared the levels of the two circulating miRNAs in the serum of patients with 
breast cancer (n= 50), fibroadenoma (n= 25), and healthy controls (n= 25). The 
miRNA SNORD68 was chosen as the housekeeping endogenous control. We found 
that the serum levels of miR-21 and miR-221 were significantly overexpressed in 
breast cancer patients compared to normal controls and fibroadenoma patients. 
Receiver Operating Characteristic (ROC) curve analysis revealed that miR-21 has 
greater potential in discriminating between breast cancer patients and the control 
group, while miR-221 has greater potential in discriminating between breast cancer 
and fibroadenoma patients. Classification models using k-Nearest Neighbor (kNN), 
Naïve Bayes (NB), and Random Forests (RF) were developed using expression levels 
of both miR-21 and miR-221. Best classification performance was achieved by NB 
Classification models, reaching 91% of correct classification. Furthermore, relative 
miR-221 expression was associated with histological tumor grades. Therefore, it may 
be concluded that both miR-21 and miR-221 can be used to differentiate between 
breast cancer patients and healthy controls, but that the diagnostic accuracy of serum 
miR-21 is superior to miR-221 for breast cancer prediction. miR-221 has more 
diagnostic power in discriminating between breast cancer and fibroadenoma patients. 
The overexpression of miR-221 has been associated with the breast cancer grade. We 
also demonstrated that the combined expression of miR-21 and miR-221can be 
successfully applied as breast cancer biomarkers.  
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Abbreviations 
ANOVA: Analysis of variance. AUC: Area under the curve.BLBC: Basal-like 
breast cancer.CDK: Cyclin-dependent kinases. CI: Confidence interval.Ct: Cycle 
threshold. EMT: Epithelial–mesenchymal transition. ER: Estrogen receptor.HCC: 
Hepatocellular carcinoma. kNN: k-Nearest Neighbor. maspin: Mammary serine 
protease inhibitor. miR-21: microRNA-21. miR-221: microRNA-221. miRNAs: 
microRNAs. mRNA: messenger RNA. NB: Naïve Bayes. PBS: Phosphate buffer 
saline. PCA: Principle component analysis. PDCD4: Programmed cell death 4. 
RF:Random Forest.ROC: Receiver Operating Characteristic.RT-PCR: Real-time 
Polymerase chain reaction. RT: Reverse transcription. SD: Standard deviation.TNBC: 
Triple negative breast cancer.TPM1: Tropomyosin 1. 
 
Introduction 
Worldwide, breast cancer is the most diagnosed cancer affecting women 
(Hortobagyi et al., 2005; Gill et al., 2007). Approximately 1.67 million new cases of 
breast cancer were diagnosed in 2012, and by 2025, this figure is predicted to escalate 
to 19.3 million. Although the highest reported prevalence of breast cancer is in 
developed countries, an increasing incidence and lower survival rate in developing 
countries has been found. This trend has been attributed to the adoption of the Western 
lifestyle (Porter, 2008), lack of breast cancer awareness and poor access to screening 
and health care services (Beaglehole and Yach, 2003; Parkin and Fernández, 2006; 
Badar et al., 2007; Rizwan and Saadullah, 2009). Breast cancer is the most frequent 
cause of cancer death in women from less developed regions (324,000 deaths, 14.3% 
of the total), and it is a leading cause of cancer death in more developed regions 
(198,000 deaths, 15.4%), second only to lung cancer (Ferlay et al., 2012; Bray et al., 
2012). 
 
According to the Egyptian National Cancer Institute (NCI), breast cancer is the 
most common type of cancer among Egyptian women, representing 18.9% of total 
cancer cases (Elatar, 2002), with an age-adjusted rate of 49.6 per 100,000 people. 
However, this represents hospital-based data from tertiary referral centers and does not 
represent all breast cancer cases in Egypt. According to the population-based cancer 
registry of Ghrabiah, Egypt, the median age at diagnosis is one decade younger than in 
Europe and North America, while most patients are premenopausal (Ibrahim et al., 
2002; Omar et al., 2003). Data from GLOBOCAN 2012 also reports that breast cancer 
is the most prevalent cancer in Egyptian women (Ferlay et al., 2012). The estimated 5-
year prevalence of all cancer types occurring in females is 49.2% (Bray et al., 2012). 
 
Fibroadenoma is the most common benign tumor occurring in female breast 
tissue (Dixon, 1991; Fechner 1988). It is normally diagnosed in young women, but 
may also occur in older women (Hunter et al., 1996). It may result from abnormal 
growth and hyperplasia of the breast lobular tissue. 
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microRNAs (miRNAs) are highly conserved noncoding RNA molecules that 
are approximately 17–25 nucleotides in length. They control gene expression at the 
posttranscriptional level by interacting with a specific target messenger RNA (mRNA) 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee et al., 2001). They also regulate a 
variety of cellular processes, such as proliferation, differentiation, metabolism, aging, 
and cell death. As such, the importance of miRNAs is increasingly recognized in 
almost all fields of biological and biomedical fields (Li et al., 2010). In humans, it has 
been estimated that there are more than 1000 miRNAs in the genome, which regulate 
approximately 30% of all protein-coding genes (Lewis et al., 2005). The importance of 
miRNAs in oncogenesis has also been recognized. Dysregulation of miRNA 
expression plays an important role in cancer development through various 
mechanisms, such as deletions, amplifications, epigenetic silencing, or mutations in 
miRNA loci (Kosaka et al., 2010). To date, an association between differentially 
expressed miRNAs and many clinicopathological features has been shown, including 
mRNA expression-based classification (Blenkiron et al., 2007), tumor grade, and 
breast cancer staging (Iorio et al., 2005). 
 
miR-21 is one of the most important miRNAs that is deregulated and over-
expressed in many malignant tumors, including breast cancers (Chan et al., 2005). 
Some studies have reported that miR-221 is also deregulated in breast cancer (Shah 
and Calin, 2011). miRNA therapy could also be a powerful tool for the treatment of 
poorly differentiated cancer (Lu et al., 2005). 
 
This study aimed to evaluate the expression level and diagnostic potential of 
serum miR-21 and miR-221 from Egyptian female patients with breast cancer, 
fibroadenoma, and healthy control subjects, regardless of the age and also to identify 
the relationship between the clinicopathological features of breast cancer and the 
expression of these miRNAs.  
 
 
Subjects and methods 
Patients 
A total of 50 female breast cancer patients (mean age ± SD: 53.5 ± 7.5) were 
assigned to the study. Patients were selected from the Kasr El-Einy Hospital, Faculty 
of Medicine in Cairo, Egypt. The serum samples were obtained from breast cancer 
patients who were recently diagnosed by mammogram and from untreated patients. 
All patients were subjected to a complete clinical examination, and a full clinical 
history was taken. Patients who had received chemotherapy/radiotherapy or who had 
an acute infection were excluded from the study, as well as patients who had cancer at 
any other site at the time of the selection. Chest radiology, liver ultrasound scanning, 
and bone scanning were used to exclude those with metastatic cancer. The 
clinicopathological characteristics of breast cancer patients, including the histological 
grade and hormone receptor status are shown in Table 1.Demographic and clinical 
features of study groups are shown in Table 2. 
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In addition, blood samples were collected from 25 female fibroadenoma 
patients (mean age ± SD: 32.1 ± 14.4) who were diagnosed by mammogram and 
breast ultrasound. In these patients, the fibroadenoma masses were solid, smooth, 
painless, and mobile, while aspiration cytology confirmed that the masses were benign 
in each patient. Additionally, a set of 25 blood samples from healthy female subjects 
(mean age ± SD: 28.6 ± 5.9) was collected from the outpatient clinic at El-Kasr El-
Einy Hospital. None of these individuals had been previously diagnosed with 
malignancies, hypertension, diabetes, or any other diseases. All procedures involving 
blood samples collection were performed by trained technicians at the outpatient clinic 
at El-Kasr El-Einy, Faculty of Medicine, Cairo University, Cairo, Egypt. All 
participants had Egyptian ethnic origin. The study was performed with the approval of 
the Faculty of Pharmacy, Cairo University local ethics committee and carried out in 
compliance with the Helsinki Declaration (2008). Informed consent was obtained from 
all of the subjects enrolled in this study. 
 
Sample collection and handling 
Peripheral blood (~10 ml) was collected from every patient by trained 
technicians. Cellular components were removed by centrifugation in two consecutive 
steps (1,500× g for 10 min at 4 °C and 2,000× g for 3 min at 4 °C, respectively). Sera 
were stored at – 80 °C until use. 
 
Methods 
Serum miRNA assays 
RNA extraction 
Total RNA, including preserved miRNAs, were extracted from 200 μl of frozen 
serum in 200 μl of Phosphate buffer saline (PBS) using a TRIzol extraction kit 
(Qiagen, Valencia, CA). QIAGEN Protease (20 μl) was added; then, 4 μl of an RNase 
A stock solution (100 mg/ml) and 200 μl of Buffer AL were added to the sample. The 
mixture was pulse-vortexed for 15 s, incubated at 56°C for 10 min in a water bath, and 
then centrifuged at room temperature at 15-25 °C for 1 min. Ethanol (200 μl, 96%) 
was added to the sample, mixed again by pulse-vortexing for 15 s, and briefly 
centrifuged. The mixture was placed in a QIAamp Mini spin column in a 2-ml 
collection tube and centrifuged at 6000x g (8000 rpm) for 1 min at room temperature. 
The QIAamp Mini spin column was then placed in a clean 2-ml collection tube, and 
the tube containing the filtrate was discarded. Buffer AW1 (500 μl) was added to the 
QIAamp Mini spin column and centrifuged at 6000x g (8000 rpm) for 1 min, and then, 
the column was placed in another clean 2-ml collection tube and the filtrate was again 
discarded. Buffer AW2 (500 μl) was added and centrifuged at 20,000x g (14,000 rpm) 
for 3 min. Then, the column was placed in a new 2-ml collection tube, the filtrate was 
discarded and the column was centrifuged at full speed for 1 min. Finally, the column 
was transferred to a new 1.5-ml collection tube and 200 μl of Buffer AE was added; 
the tube was incubated at room temperature for 1 min and then centrifuged at 6000x g 
(8000 rpm) for 1 min to elute the RNA. The RNA purity was assessed using 
NanoDrop ND-1000 (Nanodrop, USA). 
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Reverse transcription (RT) 
The RT kit that was used was made specifically for accurate analysis of the 
miRNAs from the serum samples. RT was carried out on 5 ng of total RNA in a final 
volume of 20 μl. The RT reactions (incubated for 10 min at 25 °C, 60 min at 37 °C, 5 
min at 95 °C, and then maintained at -15 °C) were performed using the RT kit 
(Qiagen, Germany) according to the manufacturer’s directions. 
 
Microarray and quantitative PCR (qPCR) 
The expression of mature miRNAs (miR-21; miR-221) was evaluated by qRT-
PCR analysis, according to the manufacturer’s directions. The housekeeping miRNA 
SNORD68 was used as an endogenous control. For RT-PCR, 5 μl of diluted RT 
products (cDNA template) was mixed with 12.5 µl of SYBR Green Master Mix 
(Qiagen, Germany), and nuclease free water was added to a final volume of 25 μl and 
dispensed into a 96-well miScript miRNA PCR array plate, which was enriched with 
forward and reverse miRNA specific primers supplied by (Qiagen, Germany). The 
plate was sealed with MicroAmp® Optical 8-Cap strips. Real-time PCR was 
performed using an Applied Biosystems 7500 Real-time PCR System (Applied 
Biosystems; Foster City, CA, USA) under the following conditions: 95°C for 15 min, 
followed by 40 cycles at 95°C for 5 s and 60°C for 34 s. The data obtained from the 
miRNA expression levels were calculated and evaluated by the cycle threshold (Ct) 
method, which is the number of cycles required for the fluorescent signal to cross the 
threshold in RT-PCR. The level of miRNA expression was reported as ΔCt value. The 
ΔCt was calculated by subtracting the Ct value of miRNA SNORD68 from the Ct 
values of the target miRNAs [mean value Ct (miR-21, miR-221) - mean value Ct 
(housekeeping gene)]. Because there is an inverse relationship between ΔCt and the 
miRNA expression level, lower ΔCt values are associated with increased miRNA. The 
resulting normalized ΔCt values were subtracted from an arbitrary reference value of 
50 to transform the data to a scale of inverted normalized Ct, where a high number 
indicates a high expression level (Barshck et al., 2010). The relative expression level 
of the miRNA of interest corresponded to the 2
-ΔCt
 value. ΔΔCt was then determined 
by subtracting the average ΔCt of the control from the ΔCt of cases. The fold change 
in the miRNA expression level was calculated (fold change = 2
-ΔΔCt
) to determine the 
relative quantitative levels of individual miRNA (Livak and Schmittgen, 2001). 
 
Statistical analyses 
The statistical analyses were performed using IBM SPSS advanced software, 
version 20 (SPSS Inc., Chicago, IL). The numerical data were expressed as the mean, 
standard deviation, range, or frequency. The qualitative data were expressed as 
frequency and percentage. For nonparametric comparison analysis between two 
groups, the Mann Whitney-U test was used, and the Kruskal-Wallis test was used for 
more than two independent variables. The Chi-square test was used to examine the 
relationship between qualitative variables; Fisher’s exact test was used instead when 
the expected frequency was less than 5. For quantitative data, the comparison between 
the 3 groups was performed by analysis of variance (ANOVA); then, the post-Hoc 
Scheffe test was used for pair-wise comparison. Power analysis was done to determine 
the statistical power and the appropriate sample size for our primary comparison of 
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miRNA among the study groups. The Receiver Operating Characteristic (ROC) curve 
was used to determine the cut-off values of miRNAs and to analyze the diagnostic 
utility of different markers. A p-value of less than 0.05 was considered statistically 
significant. All P-values are two- sided. 
 
Multivariate statistical analysis 
The aim of multivariate analysis is to cluster samples according to the captured 
variance, which in this study should be according to the expression levels of miR-21 
and miR-221. Data pre-treatment methods, namely auto-scaling and range-scaling, 
were initially considered prior to multivariate analysis. However, they show no further 
improvement in the PCA clustering; and therefore, raw expression was used to 
perform Principal Component Analysis (PCA). PCA was applied using the open-
source R statistical environment and the “prcomp” function. PCA plots were generated 
using the “ggbiplot” package. Since multivariate analysis does not allow missing 
values, only expression levels were included in the analysis. Patients’ meta-data, such 
as age, family history, diabetes, hypertension, and menopausal status, as well as other 
measurements (i.e. hormonal control, parity, number of pregnancies) were not 
available for the three groups and hence were not included in the multivariate analysis. 
Similarly, hierarchical clustering was performed based on the expression levels. Prior 
to clustering, miRNA profiles were standardized to have mean zero and standard 
deviation one. Clustering was performed using the R “gplots” and “d3Heatmap” 
libraries with average linkage and Pearson correlation. 
 
Power analysis 
The null hypothesis with > 99% power is rejected if true mean difference 
among the study groups was similar to our calculated differences. Power analysis is 
accepted if it is 80%.  The omnibus one way analysis of variance test was used in the 
analysis, with type I error probability of 0.05. Calculations were performed using 
G*Power software version 3.1.2 for MS Windows, Franz Faul, Kiel University, 
Germany. 
 
Classification modeling 
The k-Nearest Neighbors (kNN) is a machine learning method which applies 
samples distance to perform classification. Briefly, the k-closest points to the sample 
are considered, before a majority vote is applied to classify it or predict its value 
(Harrington, 2012). Naïve Bayes (NB) is a probabilistic method based on conditional 
probability. Conditional probability is the probability of an event knowing that other 
event has taken place (StatSoft, 2013). The algorithm is based on the posterior 
probability of the sample belonging to each of the classes by combining (multiplying) 
the prior probability of belonging to one class by the likelihood of the new sample 
belonging to such class. Random Forest (RF) is an ensemble method based on 
bootstrap aggregation. This method constructs multiple versions of the training data by 
sampling with replacement (bootstrapping), creates a model and makes predictions for 
all of them and combines the predictions. Boosting is quite a similar approach to 
bagging but uses weak learners –a simple algorithm that performs slightly better than 
classifying by chance– and samples are re-weighted through several iterations in order 
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to use the weights to calculate the final predictions (Kantardzic, 2005). A 
comprehensive outline and examples of the machine learning methods are available at 
(Harrington, 2012). 
 
Random forests algorithm uses bootstrap samples, creates tree models for a 
certain number of random features for each one of the bootstrap samples and 
predictions of the tree models are combined to obtain the final prediction (Fig.1). 
 
Classification models using kNN, NB, and RF were developed based on the 
expression levels of miR-21 and miR-221 of the total 100 subjects considered in this 
study. It should be noted that the patients’ metadata and other prior information were 
not incorporated within the models input to prevent the model output from being 
dependent on any prior knowledge about the samples, apart from the expression levels 
of the miR-21 and miR-221. Steps involved in developing the classification models are 
shown in Fig. 2. Firstly, input samples were randomly divided into a training and a 
testing subset consisting of 75 and 25 samples, respectively. Testing the models 
accuracy using a testing subset completely unknown to the developed models is far 
more indicative than the conventional leave-one-out cross-validation method. In order 
to ensure the balance among the three classes (Cancer, Control, and Fibroadenoma), 
we included a representative number of samples of each class in each subset. The 
training subset was then used to develop the classification models using the kNN, NB, 
and RF. For each classification approach, a grid search was performed to identify the 
optimum parameter by examining the confusion matrix of the training dataset. The 
optimized kNN, NB, and RF models were then used in order to predict the classes for 
the testing (unknown) subset created earlier. The overall model performance for each 
classifier was assessed as a percentage value based on the total number of correct 
classification divided by the total number of samples within the testing subset. The 
kNN, NB, and RF classifiers were developed using the “kNN”, “e1071”, and 
“RandomForest” R packages respectively. 
 
Results 
Demographic and clinical features of study groups 
Age in breast cancer patients was significantly different from the controls (P 
<0.001) and fibroadenoma group (P <0.001). No significant difference was revealed 
between the fibroadenoma group and the controls. A significant difference was 
observed between breast cancer and fibroadenoma patients in pre and post-menopausal 
patients (P <0.0001), family history (P <0.0001), diabetes (P <0.001) and hypertension 
(P < 0.007) (Table 2). 
 
Serum expression levels of miR-21 and miR-221  
The expression levels of miR-21 and miR-221 were evaluated by qRT-PCR. 
The serum levels of miR-21 andmiR-221 were significantly higher in cancer patients 
than in healthy control subjects, corresponding to an average fold change of 2.2 and 
2.09, respectively. They were also significantly higher in cancer patients than 
fibroadenoma patients, with an average fold change of 1.6 and 1.9, respectively at P< 
0.001 (Table 3).On the other hand, no significant increase was observed in the serum 
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levels of miR-21 and miR-221 in the fibroadenoma patients compared to the control 
group. Power analysis of serum of miR-21 and miR221 revealed power of 95%. As 
shown in Table 4, there was a significant increase in the serum expression level of 
miR-221 of tumor grade III (GIII) patients compared to GI and II patients (P< 0.05). 
The statistical analysis between the miRNA concentration and clinical and 
histopathological data did not reveal any statistical significance. 
 
Evaluation of the diagnostic accuracy of miR-21 and miR-221 
The diagnostic accuracy of miR-21 and miR-221 were evaluated using ROC 
curve analysis. ROC curve analysis showed that the two miRNAs can significantly 
differentiate between breast cancer and healthy controls, showing an area under the 
curve (AUC) of 0.98 for miR-21 (95% CI 1.0-0.96, P< 0.05) and AUC 0.97 (95% CI 
1.003-0.936, P< 0.05) for miR-221. The optimal sensitivity and specificity were (96% 
and 92%) and (94% and 88%), respectively. In addition, miR-21 and miR-221 can 
discriminate between breast cancer patients and fibroadenoma patients, showing an 
AUC 0.85 (95% CI 0.937-0.772, P<0.05) and AUC 0.93 (95% CI 0.986-0.866, 
P<0.05), respectively (Fig. 3 a-d). The optimal sensitivity and specificity were (82% 
and 76%) and (90% and 84%), respectively. 
When the diagnostic significance of serum miRNAs was compared in breast 
cancer patients, the results of the ROC curve suggested that the diagnostic accuracy of 
serum miR-21 was superior tomiR-221, with AUCs of 0.98 and 0.97, respectively. 
 
Multivariate analysis and classification models 
RT-PCR data from the two miRNAs was used as input to generate PCA to visually 
assess the intrinsic variation in the two miRNAs profiles among the three groups. The 
first principal component (PC1) captured 72.1% variance while the second one (PC2) 
captured 27.9% of variance. Control and fibroadenoma samples were more compactly 
clustered showing a small variance among subjects compared to the cancer subjects 
(Fig. 4). The same observation was seen in the heatmap hierarchical clustering in Fig. 
5, where miRNAs expression clearly separated control group from cancer group. On 
the other hand, we did not observe a clear separation of fibroadenoma group from the 
two groups. Initial separation shown using multivariate analysis indicated the 
suitability of the input dataset for classification modeling. 
 
A series of three different classifiers was developed based on RT-PCR 
measurements, in order to predict the patient categories (cancer, control, or 
fibroadenoma). The optimum parameters for each model were identified using grid 
search, these parameters were used in order to build the final set of models using the 
training subset. For kNN model, it was found that the optimum k value was achieved 
at 5. In the case of NB, the optimum classification was achieved using ~100 trees and 
by calculating the proximity measure among the rows. The overall performance for 
each model was assessed against the testing subset. Both kNN and NB models 
achieved 87.5% overall classification accuracy when tested against the randomly 
selected testing subset, while RF achieved the best performance accuracy with 97.8%. 
Furthermore, RF achieved a 100% correct classification for the cancer and 
fibroadenoma categories, while only one control sample misclassified as fibroadenoma 
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(See confusion matrices for the training and testing subsets at Table 5). We also 
examined the robustness of the three optimized models by re-running the classification 
process through a series of 100 cycles. At each cycle, the training and testing subset 
were reshuffled and the overall performance for each model was measured. The 
overall average performance also indicated that RF achieved the best performance, 
with an average of 91%, followed by NB at 88%, and kNN at 82.3% (Fig. 6). The 
models stabilized after ~30 iterations, indicating a very good stability of the classifiers 
in terms of prediction accuracy. 
 
 
Discussion 
The expression patterns and levels of specific miRNAs could reflect altered 
physiological and pathological conditions. Due to their high stability in human serum, 
they represent attractive novel diagnostic biomarkers for certain health conditions, 
such as cancer. miRNAs are associated with the regulation of oncogenes and tumor 
suppressor genes. Previous research has shown that their disruption is related to many 
types of cancer (Lu et al., 2005; Shenouda and Alahari, 2009; Garofalo et al., 2010; 
Kouhkam et al., 2011), including breast cancer (Iorio et al., 2005). 
 
In the present study, we set out to analyze the expression patterns of miR-21 
and miR-221 as a single biomarker. Our results demonstrated that serum levels of 
miR-21 and miR-221 are significantly increased in breast cancer patients compared to 
those of fibroadenoma patients and healthy control subjects. We found that the 
expression levels of these two miRNAs can significantly discriminate between breast 
cancer patients and healthy subjects, with high specificity and sensitivity using ROC 
curve analysis and a fold change of 2.2 and 2.09, respectively. The results showed that 
miR-21 has considerable diagnostic power in discriminating between breast cancer 
patients and control subjects, yielding an AUC of 0.98 with a sensitivity of 96% and a 
specificity of 92%. Moreover, miR-21 andmiR-221 can discriminate between breast 
cancer and fibroadenoma patients. miR- 221 has more diagnostic power than miR-21, 
yielding an AUC of 0.93 with a sensitivity of 90% and a specificity of 84%. With 
regard to the clinicopathological features, miR-221 was significantly overexpressed in 
grade III compared to Grade I and II, with a fold change of 1.3.  
 
We thoroughly tested the robustness and specificity of using the expression 
levels for miR-21 and miR-221 by developing and comparing the performance of three 
classification models using kNN, NB, and RF. All three models achieved high 
prediction accuracies, reaching a top performance at 97.8% for RF. Furthermore, the 
developed RF model achieved a 100% correct classification for both cancer and 
fibroadenoma categories, indicating a promising potential of successfully using miR-
21 and miR-221 biomarkers for breast cancer. 
 
In general, high serum miRNA levels in cancer patients are due to excessive 
secretion by primary cancer cells (Mitchel et al., 2008). Previous studies have shown 
that miRNAs can be selectively secreted into the bloodstream via small membrane 
vesicles, such as exosomes (Gallo et al. 2012), that are released into the extracellular 
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environment (Mathivanan et al., 2010). A study has shown that cellular gene products, 
including miRNAs, are packaged inside exosomes and are delivered to the target cells, 
where they have a biological effect (Ohshima et al., 2010). 
 
miR-21 is one of the most important miRNAs associated with cell migration 
and the invasiveness of breast cancer cells, thus contributing to tumor progression and 
metastasis (Han et al., 2012a; Han et al., 2012b). Chan et al. (2005) reported the 
aberrant expression of miR-21 in glioblastoma. Previous research has shown that miR-
21, along with other miRNAs, is over-expressed in human breast cancer (Iorio et al., 
2005).  
 
Our results from this study coincide with previous research (Iorio et al., 2005; 
Si et al., 2007), showing a significant overexpression of miR-21 in breast cancer 
patients, which suggests that it acts as an oncogene (Yan et al., 2008). Previous 
research has shown that the mammary serine protease inhibitor (maspin) and 
programmed cell death 4 (PDCD4), which are involved in invasion and metastasis, 
have been identified as targets for miR-21 (Zhu et al., 2008). Maspin plays an 
important role in breast cancer, as it suppresses invasion and metastasis with its ability 
to induce apoptosis, thus suppressing angiogenesis (Brew et al., 2000; Bailey et al., 
2006; Song et al., 2012). PDCD4 induces the expression of p21, which acts as an 
inhibitor of cyclin-dependent kinases (CDK) (Frankel et al., 2008), therefore playing a 
role in apoptosis. Altered function of miR-21 inhibits PDCD4, encouraging 
uncontrolled cellular growth and cancer progression. In addition, another study 
confirmed that miR-21 targets the tumor suppressor tropomyosin 1 (TPM1). This is a 
member of the tropomyosin family of proteins, which are associated with actin and 
serve to stabilize microfilaments and act as tumor suppressor genes (Perry, 2001, Zhu 
et al., 2007). Thus, the downregulation of TPM1 by miR-21 suppression may explain 
the inhibition of tumor invasion. Suppression ofmiR-21 by anti-miR-21 is linked with 
reduced cell proliferation in vitro and tumor growth in vivo (mouse model) (Corcoran 
et al., 2011). 
 
miR-21 overexpression is associated with an advanced clinical stage and lymph 
node metastasis in human breast cancer and is also associated with low sensitivity and 
a poor response to chemotherapy (Yan et al., 2008; Krichevsky et al., 2009). Our 
results showed that overexpression of serum miR-21 does not appear to correlate 
significantly with tumor grade or discriminate between different receptor statuses. 
 
miR-221, encoded on human chromosome X, is overexpressed in many 
aggressive carcinomas (Galardi et al., 2007; Waters et al., 2012; Nassirpour et al., 
2013; Wang et al., 2013), including breast cancer (Radojicic et al., 2011; Waters et al., 
2012; Nassirpour et al., 2013). Furthermore, an elevated expression level of miR-221 
in certain carcinomas facilitates invasion (Waters et al., 2012), a larger tumor size (Li 
et al., 2011), early metastasis (Liu et al., 2012), and a shorter time to recurrence (Kang 
et al., 2012). Fornari et al. (2008) established a potential oncogenic function of miR-
221, which is upregulated in Hepatocellular carcinoma (HCC). It has been reported 
that miR-221 targets the cyclin-dependent kinase inhibitors CDKN1B/p27 and 
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CDKN1C/p57. Upregulation of miR-221 causes a downregulation of these inhibitors 
and promotes the loss of cell cycle control (le Sage et al., 2007; Pineau et al., 2010). 
Other studies have shown that miR-221 regulates two key mechanisms that promote 
the aggressive tumorigenic characteristics observed in triple negative breast cancer 
(TNBC): it promotes cell cycle progression by inhibiting the protein cyclin-dependent 
kinase (p27kip1) and promotes epithelial–mesenchymal transition (EMT) by inhibiting 
the expression of E-cadherin. Both of these mechanisms may account for the 
aggressive cellular proliferation, suppression of apoptosis, as well as higher cell 
migration and invasiveness associated with basal-like breast cancer (BLBCs) and 
TNBCs (Dudda et al., 2013; Manavalan et al., 2013). Previous research has shown that 
miR-221 is involved in suppressing ERα expression in luminal breast cancer cells and 
EMT transition in basal-like breast cancers (Miller et al., 2008; Rao et al., 2011). 
Moreover, it has been reported that miR-221 is involved in the promotion of an 
aggressive basal-like breast cancer phenotype, functioning downstream of the RAS 
pathway and triggering epithelial-to-mesenchymal transition (EMT) (Wang et al., 
2011). Other studies have shown the predictive role of miR-221 in resistance to 
neoadjuvant chemotherapy (Kawaguchi et al., 2013; Wurz et al., 2010). 
 
In conclusion, our data and statistical analysis indicate that miR-21 and miR-
221 are indeed good candidates to be used as molecular diagnostic markers for breast 
cancer, specially when their expression levels is combined with machine learning 
algorithms to accurately predict the patient categories. An important finding is that the 
overexpression of miR-221 is associated with the breast cancer grade. In addition, 
miR-221 has more diagnostic power in discriminating between breast cancer and 
fibroadenoma patients, which makes it a potential marker that may enhance the 
discriminating power of this plasma quantitation test in the future.  
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Fig. 1. Random forest algorithm summary. 
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Fig. 2.  Flowchart illustrating the development process for machine learning classifiers. 
The original dataset is split randomly into training and testing subset. The split 
algorithm ensures enough representable samples within each class. The optimum 
parameters are used to build the optimized classifiers, which is then used to assess the 
prediction accuracy of the testing subset; which is a representative of unknown dataset. 
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Fig.3. P of the ROC of miR-21 (a) and miR-221 (c) between breast cancer patients and 
control groups, and P of the ROC of miR-21 (b) and miR-221 (d) between breast cancer 
patients and fibroadenoma groups 
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Fig. 4. Multivariate analysis using a biplot principal component analysis (PCA) using 
miRNA expression to differentiate between breast cancer, fibroadenoma and normal 
controls. The red dots indicate the cancer group, the blue dots indicate fibroadenoma 
patients, while the green dots indicate the control samples. The first principle 
components (PC1) accounted for 72.1%, while the second principle component (PC2) 
accounts for 27.9% of the variance (Total 100% of variance). 
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Fig. 5. Heatmap clusters showing expression levels for miR-21 and miR-221 across 
100 samples. Color ramp indicate the expression level; ranging from yellow (low 
expression) to dark blue (high expression. Each row represents an individual, and each 
column represents the corresponding miRNA.  
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Fig. 6. Overall performances of the k-Nearest Keibours (kNN), Naïve Bayes (NB), 
and Random Forests (RF) models. The best prediction accuracy was achieved by RF, 
with an average of 91%, followed by NB at 88%, and kNN at 82.3% 
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Table 1. Clinicopathological characteristics of breast cancer patients 
 
Parameters Patients frequency 
Total  50 
Age  Range (37- 70 years) 
Less than 55 31 
More than 55 19 
Distant metastasis   
M0 50 
Family History  
Positive 28 
Negative 22 
Tumor type  
Invasive Ductal Carcinoma 46 
Invasive Lobular Carcinoma 4 
Grading  
G I, II 37 
G III 13 
Tumor Stage  
T2 35 
T3 15 
Lymph node metastasis  
N 1 6 
N 2 30 
N3 14 
Estrogen receptor  
Positive 8 
Negative 42 
Progesterone receptor  
Positive 7 
Negative 43 
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Table 2. Demographic and clinical features of study groups 
 
 
 
Parameters 
Control 
N=25 
Fibroadenoma 
N=25 
Breast 
cancer 
N=50 
P value 
Age 
28.6 ± 
8.5 
32.1 ±14.4 
53.5 ± 
7.5
ab
 
<0.001* 
Menstrual 
history 
Pre-
menopause 
23 21 13 
<0.0001* 
Post- 
menopause 
2 4 37 
Family history 
Yes - 5 28 
<0.0001* 
No 25 20 22 
Diabetes 
Yes - - 13 
<0.001* 
No 25 25 37 
Hypertension 
Yes - 2 12 
0.007* 
No 25 23 38 
 
 
 
Values are expressed as the means ± S.D (age) or frequency. * Indicates statistical 
significance. P values < 0.05 are considered significant.  
        
      Clinical data were analyzed by a. ANOVA and b. Chi square test and Fisher’s exact 
test.  
a Statistical significance from the control group 
b Statistical significance from the fibroadenoma group 
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Table 3.  Relative expression level of serum miR-21 and miR-221 in breast cancer 
patients, fibroadenoma patients, and the control group 
 
Variables No. miR-21 miR-221 
Control  25 1.0 ± 0.1 1.1 ± 0.1 
Fibroadenoma 25 1.3 ± 0.2 1.2 ± 0.2 
Breast Cancer 50 2.2 ± 0.8
a, b 
2.3 ± 0.8
a, b
 
All values are expressed as mean ± SD 
a. Statistical significance from control group 
b. Statistical significance from fibroadenoma group 
Significance at P < 0.05 
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Table 4. Correlation between the relative expression of serum miRNA values and 
patient clinicopathological characteristics at the time of primary breast cancer 
diagnosis  
 
 
                   All values are expressed as mean ± SD. 
Mann-Whitney U and Kruskal-Wallis nonparametric test 
were used for comparing different groups. 
                P*: Indicates statistical significance at P < 0.05 
 
 
 
 
 
 
 
Parameters miR- 21 P value miR- 221 P value 
Age   
Less than 55 2.2 ± 0.8 
0.582
 2.2 ± 0.9 
0.147 
More than 55 2.1 ± 0.8 2.1 ± 0.7 
Distant metastasis      
M0 2.2 ± 0.8  2.3 ± 0.8  
Family History     
Positive 2.1 ±0.6 
0.868 
2.2 ± 0.8 
0.646 
Negative 2.2 ± 1.0 2.4 ± 0.9 
Tumor type     
Invasive Ductal Carcinoma 2.2 ± 0.8 
0.569 
2.2 ± 0.7 
0.357
 
Invasive Lobular Carcinoma 1.9 ± 0.5 3.0 ± 1.6 
Grading     
G I&II 2.2 ± 0.8 
0.912
 2.1 ± 0.7 
0.038* 
G III 2.1 ± 0.6 2.8 ± 1.1 
Tumor Stage     
T2 2.3 ± 0.8 
0.112 
2.3 ± 0.8 
0.824 
T3 1.9 ± 0.6 2.3 ± 0.8 
Lymph node metastasis     
N 1 2.0 ± 0.8 
0.877 
1.9 ± 0.5 
0.344 N 2 2.2 ± 0.8 2.3 ± 1.0 
N3 2.1 ± 0.7 2.4 ± 0.7 
Estrogen receptor     
Positive 2.4 ± 1.0 
0.427
 2.9 ± 1.0 
0.099
 
 
Negative 2.1 ± 0.7 2.2 ± 0.7 
Progesterone receptor     
Positive 2.2 ± 0.8 0.870 3.0 ± 1.0  
0.056 
Negative 2.2 ± 0.8 2.2 ± 0.7 
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Table 5. Confusion matrices for the training and testing subsets 
KNN Training Confusion 
Matrix 
 Testing Confusion Matrix 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
Cancer 36 1 4 Cancer 12 0 0 
Control 1 16 5 Control 0 5 2 
Fibroadeno
ma 
1 2 10 Fibroaden
oma 
0 1 4 
        
Naïve Bayes Training Confusion 
Matrix 
 Testing Confusion Matrix 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
Cancer 38 0 0 Cancer 11 0 0 
Control 0 19 0 Control 0 5 1 
Fibroadeno
ma 
0 0 19 Fibroaden
oma 
1 1 5 
        
Random 
Forests 
Training Confusion 
Matrix 
 Testing Confusion Matrix 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
predicted Canc
er 
Cont
rol 
Fibroaden
oma 
Cancer 38 0 0 Cancer 12 0 0 
Control 0 19 0 Control 0 5 0 
Fibroadeno
ma 
0 0 19 Fibroaden
oma 
0 1 6 
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Abbreviations 
 
 ANOVA: Analysis of variance.  
 AUC: Area under the curve.  
 BLBC: Basal-like breast cancer.  
 CDK: Cyclin-dependent kinases.  
 CI: Confidence interval.  
 Ct: Cycle threshold.  
 EMT: Epithelial–mesenchymal transition.  
 ER: Estrogen receptor.  
 HCC: Hepatocellular carcinoma.  
 kNN: k-Nearest Neighbor.  
 maspin: Mammary serine protease inhibitor.  
 miR-21: microRNA-21.  
 miR-221: microRNA-221.  
 miRNAs: microRNAs.  
 mRNA: messenger RNA.  
 NB: Naïve Bayes.  
 PBS: Phosphate buffer saline.  
 PCA: Principle component analysis.  
 PDCD4: Programmed cell death 4.  
 RF: Random Forest.  
 ROC: Receiver Operating Characteristic.  
 RT-PCR: Real-time Polymerase chain reaction.  
 RT: Reverse transcription.  
 SD: Standard deviation.  
 TNBC: Triple negative breast cancer.  
 TPM1: Tropomyosin 1.  
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Research Highlights 
 
 MiRNA- 21 and 221 can significantly differentiate between breast cancer and 
healthy controls. 
 The diagnostic accuracy of serum miRNA-21 is superior than miRNA-221 for 
breast cancer prediction. 
 MiRNA-221 has more diagnostic power than miRNA-21 in discriminating 
between breast cancer and fibroadenoma patients. 
